327 related articles for article (PubMed ID: 34807428)
21. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
22. Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib.
Simpson EL; Wollenberg A; Bissonnette R; Silverberg JI; Papacharalambous J; Zhu L; Zhang W; Beebe JS; Vincent M; Peeva E; Bushmakin AG; Cappelleri JC; Chen L; Sikirica V; Xenakis J
Dermatitis; 2021 Oct; 32(1S):S53-S61. PubMed ID: 33795561
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials.
Meher BR; Mohanty RR; Padhy BM
J Dermatolog Treat; 2022 Jun; 33(4):2335-2343. PubMed ID: 34315323
[TBL] [Abstract][Full Text] [Related]
24. Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis.
Wojciechowski J; Malhotra BK; Wang X; Fostvedt L; Valdez H; Nicholas T
Clin Pharmacokinet; 2022 May; 61(5):709-723. PubMed ID: 35061234
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
Wan H; Jia H; Xia T; Zhang D
Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
[TBL] [Abstract][Full Text] [Related]
26. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
Blauvelt A; Silverberg JI; Lynde CW; Bieber T; Eisman S; Zdybski J; Gubelin W; Simpson EL; Valenzuela F; Criado PR; Lebwohl MG; Feeney C; Khan T; Biswas P; DiBonaventura M; Valdez H; Cameron MC; Rojo R
J Am Acad Dermatol; 2022 Jan; 86(1):104-112. PubMed ID: 34416294
[TBL] [Abstract][Full Text] [Related]
27. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
Ferreira S; Guttman-Yassky E; Torres T
Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
[TBL] [Abstract][Full Text] [Related]
28. Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies.
Kim BS; Silverberg JI; Ständer S; Yosipovitch G; Simpson EL; DiBonaventura M; Kerkmann U; Farooqui SA; Biswas P; Valdez H; Cameron MC
Dermatitis; 2021 Oct; 32(1S):S39-S44. PubMed ID: 34175862
[TBL] [Abstract][Full Text] [Related]
29. Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
Wang EQ; Le V; O'Gorman M; Tripathy S; Dowty ME; Wang L; Malhotra BK
J Clin Pharmacol; 2021 Oct; 61(10):1311-1323. PubMed ID: 33749838
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of abrocitinib for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis: update of a living systematic review and meta-analysis.
Zheng H; Chen Y; Xu Y; Deng X
Eur J Dermatol; 2023 Oct; 33(5):530-543. PubMed ID: 38297930
[TBL] [Abstract][Full Text] [Related]
31. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
Silverberg JI; Thyssen JP; Simpson EL; Yosipovitch G; Ständer S; Valdez H; Rojo R; Biswas P; Myers DE; Feeney C; DiBonaventura M
Am J Clin Dermatol; 2021 Jul; 22(4):541-554. PubMed ID: 33954933
[TBL] [Abstract][Full Text] [Related]
32. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
J Dermatol; 2023 Jan; 50(1):e1-e19. PubMed ID: 36412059
[TBL] [Abstract][Full Text] [Related]
33. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life.
Blauvelt A; Boguniewicz M; Brunner PM; Luna PC; Biswas P; DiBonaventura M; Farooqui SA; Rojo R; Cameron MC
J Dermatolog Treat; 2022 Aug; 33(5):2605-2613. PubMed ID: 35763326
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis.
Narla S; Silverberg JI
Dermatitis; 2024; 35(S1):S24-S38. PubMed ID: 37527229
[No Abstract] [Full Text] [Related]
35. Successful treatment of alopecia universalis with abrocitinib: a case report.
Zhang J; Zuo YG
J Dermatolog Treat; 2023 Dec; 34(1):2242706. PubMed ID: 37526039
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
37. The suitability of treating atopic dermatitis with Janus kinase inhibitors.
Narla S; Silverberg JI
Expert Rev Clin Immunol; 2022 May; 18(5):439-459. PubMed ID: 35377276
[TBL] [Abstract][Full Text] [Related]
38. JAK inhibitors in the treatment of atopic dermatitis.
Chovatiya R; Paller AS
J Allergy Clin Immunol; 2021 Oct; 148(4):927-940. PubMed ID: 34437922
[TBL] [Abstract][Full Text] [Related]
39. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
40. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Simpson EL; Silverberg JI; Nosbaum A; Winthrop KL; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Zhang M; Farooqui SA; Romero W; Thorpe AJ; Rojo R; Johnson S
Am J Clin Dermatol; 2021 Sep; 22(5):693-707. PubMed ID: 34406619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
